The new mouse embryo model system promises to spur research into developmental health and disease.
List view / Grid view
University of Cambridge
A new study has shown that nanobodies derived from llamas could have the potential to destroy human cytomegalovirus.
Drug Target Review’s Ria Kakkad recently visited ELRIG and the British Pharmacological Society’s conference on New Modalities in Pharmacology and Drug Discovery which took place in London, UK. This article shares some of the key takeaways from the event.
A recent whole genome sequencing study has revealed hidden insights into the causes of cancer. In an exclusive article, Dr Andrea Degasperi from the Early Cancer Institute at the University of Cambridge, UK spoke to Drug Target Review's Ria Kakkad about the study's implications and the future of whole genome sequencing.
Ultra-powerful 7T MRI scanners could be used to help identify those patients with Parkinson’s disease and similar conditions most likely to benefit from new treatments for previously untreatable symptoms.
Two new papers from the Human Cell Atlas shed new light on the types and traits of immune cells that can be found in the human body, from developmental stages to adulthood.
DNA analysis of thousands of tumours has uncovered insights about the causes of cancer, with genetic mutations providing a personal history of the damage and repair processes each patient has been through.
Researchers have shown that it could be possible to modify the mitochondrial genome, paving the way for new treatments for incurable mitochondrial diseases.
Scientists have developed a drug called STM2457 which inhibits a key enzyme involved in acute myeloid leukaemia.
For the first time, scientists have grown bile duct organoids that could repair damaged ducts and livers as a new cell therapy.
A team has revealed how SARS-CoV-2 infects cells, suggesting that targeting its RNA with drugs would stop the virus replicating.
A study has identified more than 200 genes that drive the progression of glioblastoma and which the researchers say present drug targets.
Researchers have developed a video and model-building programme for other scientists to build full-length COVID-19 S protein models.
Two studies reveal the importance of timing in Huntington’s disease interventions and demonstrate interleukin-6 may play a protective role.